These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 38555280)
1. PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma. Cao J; Zeng K; Chen Q; Yang T; Lu F; Lin C; Zhan J; Ma W; Zhou T; Huang Y; Luo F; Zhao H Cell Death Dis; 2024 Mar; 15(3):237. PubMed ID: 38555280 [TBL] [Abstract][Full Text] [Related]
2. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines. Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH Cells; 2021 Oct; 10(11):. PubMed ID: 34831139 [TBL] [Abstract][Full Text] [Related]
3. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751 [TBL] [Abstract][Full Text] [Related]
4. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts. Lin YT; Wang HC; Chuang HC; Hsu YC; Yang MY; Chien CY J Mol Med (Berl); 2018 Dec; 96(12):1407-1418. PubMed ID: 30374682 [TBL] [Abstract][Full Text] [Related]
5. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458 [TBL] [Abstract][Full Text] [Related]
6. ADORA1 promotes nasopharyngeal carcinoma cell progression through regulation of PI3K/AKT/GSK-3β/β-catenin signaling. Pan S; Liang S; Wang X Life Sci; 2021 Aug; 278():119581. PubMed ID: 33961854 [TBL] [Abstract][Full Text] [Related]
7. Chloroform extract from Sophora Tonkinensis Gagnep. inhibit proliferation, migration, invasion and promote apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway. ShuoWang ; Song Z; Gong X; Ou C; Zhang W; Wang J; Yao C; Qin S; Yan B; Li Q; Wei K; Hou X; Zhou X; Miao J J Ethnopharmacol; 2021 May; 271():113879. PubMed ID: 33524509 [TBL] [Abstract][Full Text] [Related]
8. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling. Liu Y; Liu Q; Chen S; Liu Y; Huang Y; Chen P; Li X; Gao G; Xu K; Fan S; Zeng Z; Xiong W; Tan M; Li G; Zhang W FASEB J; 2019 Nov; 33(11):11959-11972. PubMed ID: 31408612 [TBL] [Abstract][Full Text] [Related]
9. Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway. Wang J; Shang Y; Wang Y; Li Y; Wang L; Huang S; Lyu X Histol Histopathol; 2024 May; 39(5):647-657. PubMed ID: 37971211 [TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Luo F; Lu FT; Qiu MZ; Zhou T; Ma WJ; Luo M; Zeng KM; Luo QY; Pan WT; Zhang L; Xia ZF; Zhang ZH; Cao JX; Zhao HY; Zhang L; Yang DJ Cell Death Dis; 2021 Aug; 12(8):772. PubMed ID: 34354046 [TBL] [Abstract][Full Text] [Related]
11. Cystathionine γ-lyase mediates cell proliferation, migration, and invasion of nasopharyngeal carcinoma. Zhang Q; Gao Y; Zhang Y; Jing M; Wang D; Wang Y; Khattak S; Qi H; Cai C; Zhang J; Ngowi EE; Khan NH; Li T; Ji A; Jiang Q; Ji X; Li Y; Wu D Oncogene; 2022 Dec; 41(49):5238-5252. PubMed ID: 36310322 [TBL] [Abstract][Full Text] [Related]
13. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway. Xie Z; Li W; Ai J; Xie J; Zhang X J Transl Med; 2022 Jun; 20(1):264. PubMed ID: 35676661 [TBL] [Abstract][Full Text] [Related]
14. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654 [TBL] [Abstract][Full Text] [Related]
15. Upregulation of lncRNA HAGLROS enhances the development of nasopharyngeal carcinoma via modulating miR-100/ATG14 axis-mediated PI3K/AKT/mTOR signals. Zhang W; Zhang Y; Xi S Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3043-3052. PubMed ID: 31334669 [TBL] [Abstract][Full Text] [Related]
16. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress. Li Q; Ni W; Deng Z; Liu M; She L; Xie Q Fundam Clin Pharmacol; 2017 Jun; 31(3):301-310. PubMed ID: 28078787 [TBL] [Abstract][Full Text] [Related]
17. Lactoferrin mediates epithelial-mesenchymal transformation by regulating the PI3K/AKT/mTOR pathway to inhibit nasopharyngeal carcinoma metastasis. Xu M; Fan Y; Zou G; Yang Q; Xu F Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):130-135. PubMed ID: 38650146 [TBL] [Abstract][Full Text] [Related]
18. Sodium butyrate induces autophagic apoptosis of nasopharyngeal carcinoma cells by inhibiting AKT/mTOR signaling. Huang W; Zeng C; Liu J; Yuan L; Liu W; Wang L; Zhu H; Xu Y; Luo Y; Xie D; Jiang X; Ren C Biochem Biophys Res Commun; 2019 Jun; 514(1):64-70. PubMed ID: 31023529 [TBL] [Abstract][Full Text] [Related]
19. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma. Chen Y; He Q; Ma H; Zhang L; Liu F; Han Y Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):165-173. PubMed ID: 35545406 [TBL] [Abstract][Full Text] [Related]
20. Targeting Glutamine Metabolism through Glutaminase Inhibition Suppresses Cell Proliferation and Progression in Nasopharyngeal Carcinoma. Su C; Li M; Yang Y; Wang Z; Wang Q; Wang W; Ma X; Jie R; Chen H; Li X; Lu J Anticancer Agents Med Chem; 2023; 23(17):1944-1957. PubMed ID: 37497684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]